Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
The University of Texas MD Anderson Cancer Center · University Health Network · +32 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,699
total citations
- FWCI
- 65.46
- Percentile
- 100%
- References
- 28
Citations per year
Authors
117- RLRobert L. ColemanCorresponding
The University of Texas MD Anderson Cancer Center
- AMAmit M. Oza
University Health Network, Princess Margaret Cancer Centre
- DLDomenica Lorusso
Fondazione IRCCS Istituto Nazionale dei Tumori
- CACarol Aghajanian
Memorial Sloan Kettering Cancer Center
- AOAna Oaknin
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Oncology
- Internal medicine
- Ovarian carcinoma
- Double blind
- Ovarian cancer
- Surgery
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- UDU.S. Department of DefenseAward: OC120506
- AAAmerican Association for Cancer Research
- OCOvarian Cancer Research Fund
- AAmgen
- AAstraZeneca
- MMerck
- RRoche
- AAbbVie
- MSMemorial Sloan-Kettering Cancer Center
- OPOncoMed Pharmaceutical
- ABArray BioPharma
- RPRegeneron Pharmaceuticals
- NONational Ovarian Cancer CoalitionAward: SU2C-AACR-DT16–15
- COClovis Oncology
- UCUniversity College London
- APAjinomoto Pharmaceuticals
- GGenentech
- ESEMD Serono
- SUStand Up To Cancer
- JBJanssen Biotech